GlassScriptPhysician profile
Jonathan Nix
NPI 1811087299
$7,524.80
in general payments reported to CMS, 2019-2025
27 companies · $2,362 in 2025
The $2,362 reported for 2025 was more than what 97% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $707 · 2022: $1,216 · 2023: $1,293 · 2024: $1,947 · 2025: $2,362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,601.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,487.49 | 2021-2025 | |
| Genzyme Corporation | $1,232.47 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $633.73 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $536.04 | 2021-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $532.73 | 2023-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $452.27 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $306.77 | 2021-2025 | Ilumya |
| Incyte Corporation | $305.08 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $270.68 | 2024-2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $264.41 | 2021-2025 | Jublia, Siliq, Duobrii |
| Amgen INC. | $211.72 | 2022-2024 | Otezla |
| Pfizer INC. | $169.33 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $162.33 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $150.70 | 2024-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $120.63 | 2021-2025 | Ebglyss, Taltz, Olumiant |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $119.54 | 2023-2024 | Vtama |
| Ucb, INC. | $112.18 | 2021-2024 | Bimzelx |
| Mayne Pharma Commercial LLC | $103.93 | 2023-2025 | |
| Organon LLC | $69.05 | 2025 | Vtama |
| Genentech USA, INC. | $65.42 | 2021-2022 | |
| Verrica Pharmaceuticals INC. | $38.18 | 2023 | Ycanth |
| Tersera Therapeutics LLC | $38.00 | 2022 | |
| Globus Medical, INC. | $36.99 | 2025 | Vyrsa V1 |
| Stimwave Technologies Incorporated | $35.06 | 2022 | |
| Almirall LLC | $28.20 | 2021 | |
| Botanix Sb INC | $22.99 | 2025 | Sofdra |
| Organogenesis INC. | $18.88 | 2023 | Puraply |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Nix listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.